|
Canada-0-ARTISTS Directorios de empresas
|
Noticias de la compañía :
- Philip Tedeschi - Vice President - Immunovant - LinkedIn
I am currently the Senior Director of Translational Science and Immunology at Immunovant where I oversee the development and conduct of our pre- and non-clinical programs as
- Our Leadership :: Immunovant, Inc. (IMVT)
Philip Tedeschi, PhD, MS Vice President, Translational Sciences and Clinical Laboratories Phil is a translational scientist who brings more than 15 years of drug development knowledge for both small and large molecule programs His expertise includes biomarkers, bioanalysis and toxicology
- Philip Tedeschi - Vice President at Immunovant - The Org
Philip Tedeschi serves as Vice President at Immunovant since July 2020, where responsibilities include leading pre-clinical and non-clinical efforts for IMVT-1402, overseeing the development of clinical protocols, and authoring critical clinical documents
- Philip Tedeschi - Executive Bio, Work History, and Contacts - Equilar . . .
View the executive profile of Philip Tedeschi, Vice President, Translational Sciences and Clinical Laboratories at Immunovant, Inc , on Equilar ExecAtlas to see current and past work history and gain access to Philip Tedeschi's network of 45 business contacts
- Philip Tedeschi Email Phone number - ZoomInfo
Philip Tedeschi is a Vice President at Immunovant based in New York City, New York Previously, Philip was a Senior Director, Translational Science and Immunology at Immunovant and also held positions at Pfizer, Adello Biologics, Rutgers Cancer Institute of New Jersey, BioReliance
- Philip Tedeschi, Immunovant Inc: Profile and Biography
Philip Tedeschi is Sr VP:Translational Sciences Clinical Laboratories at Immunovant Inc See Philip Tedeschi's compensation, career history, education, memberships
- Philip Tedeschis email phone | Immunovants Senior Director . . .
Philip's Workplace Immunovant Immunovant, a member of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the t Read More
- Philip Tedeschi on LinkedIn: Been a long 2. 5 year ride, but it’s great . . .
Been a long 2 5 year ride, but it’s great to see IMVT-1402 human data out in public and so well-received! Read more about the positive initial IMVT-1402 Phase 1 SAD and 300 MG subcutaneous MAD
- Philip Tedeschi - Senior Director, Clinical Laboratories at Immunovant . . .
View Philip Tedeschi's email address (p*****@immuno*** com) and phone number Philip works at Immunovant as Senior Director, Clinical Laboratories Philip is based out of New York, New York, United States and works in the Biotechnology Research industry
- Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn . . .
Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED) We report the first clinical studies of an FcRn inhibitor, batoclimab, in TED Proof-of-concept (POC) and randomized, double-blind placebo-controlled trials Multicenter
|
|